Therefore, COS may prevent or treat colitis by suppressing the production of inflammatory factors, preventing the inflammation response via activating PPARγ and SIRT1, inhibiting the acetylation and phosphorylation of NF-κB p65, and optimizing the intestinal microbiota composition. This evidence concerns the gene SIRT1 and colitis.